Retrospective review of megestrol use for weight loss in an elderly veteran population.
OBJECTIVE
Evaluate the efficacy of megestrol acetate therapy for nonmalignancy and/or non-AIDS-related weight loss in the elderly.


METHODS
Retrospective chart review.


METHODS
Inpatients or outpatients at the West Palm Beach Veterans Affairs Medical Center.


METHODS
Two inclusion criteria were applied: patients older than 65 years and patients initiated on megestrol therapy from January 1 to December 31, 2002. All eligible patients meeting the above criteria were eligible for inclusion in the study. Patients who had a diagnosis of malignancy and/or AIDS, no baseline weight, no follow-up weights, no record of laboratory values, and/or were receiving enteral or parenteral nutrition available at the West Palm Beach Veterans Affairs Medical Center, were excluded. Patients who received megestrol therapy for less than one week also were excluded.


METHODS
Weight loss in the previous six months, baseline weight, follow-up weights at 3, 6, 9, and 12 months after megestrol initiation, baseline and follow-up albumin for 12 months after megestrol initiation, and any adverse effects from megestrol.


RESULTS
Fifty-seven patients (males 56, females 1) were included. The average age was 78.5 years old. The average duration of therapy was 3.2 months, and the average starting dose of megestrol was 436 mg per day. At baseline, patients were, on average, 102% of their ideal body weight. Baseline measurement of albumin was obtained in 89% (N = 23) of patients. Six out of 23 (26%) patients had a baseline albumin less than 3 g/dL. The average baseline albumin was 3.6. Weight loss in the six months prior to megestrol initiation occurred in 63% of patients. Over the 12-month follow-up period, the percentage of patients who gained weight was 40%, lost weight was 49%, and had no change in weight was 11%. There were no differences in baseline characteristics between the patients who did or did not gain weight during the 12-month period after megestrol initiation. No documented adverse side effects were attributed to megestrol.


CONCLUSIONS
Patients both gained and lost weight when receiving megestrol therapy. There was no difference between the patients who did or did not gain weight using objective measures of weight loss.
Kennedy
Deborah H
DH
Nova Southeastern University College of Pharmacy, West Palm Beach Program, Palm Beach Gardens, Florida, USA. deborah.kennedy@bms.com
Ward
Ceressa T
CT
Salvig
Brent
B